Last reviewed · How we verify
CANDICIDIN
At a glance
| Generic name | CANDICIDIN |
|---|---|
| Drug class | candicidin |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Candidiasis of vagina
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CANDICIDIN CI brief — competitive landscape report
- CANDICIDIN updates RSS · CI watch RSS